Status: Recruiting
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma
To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.
Participants needed: 64
Trial details
Age: 1-21Biological sex: AllType: ObservationalSponsor: Guangzhou Women and Children's Medical CenterUpdated: Aug 28, 2024Locations: 1
Eligibility criteria
Children with newly diagnosed stage 4 neuroblastoma according to the Internation... [+2]